Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis

NCT03889639 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03889639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03889639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2019
Completion date
January 2, 2020
Enrollment
130 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis